HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America.

AbstractAIMS:
The objective of this study was to evaluate the safety and efficacy of pregabalin at flexible doses of 150-600 mg/day in Latin American patients with neuropathic pain.
METHODS:
A prospective, multicentre, open-label, non-comparative study included patients age >or= 18 years diagnosed with neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathic pain (PNP), or human immunodeficiency virus-related PNP. Eligible patients (N = 121) had a score of >or= 40 mm on the visual analogue scale and a daily pain rating scale (DPRS) score of >or= 4 throughout screening. Patients received flexible-dose pregabalin (150-600 mg/day) for 12 weeks, which included a 4-week dose-adjustment phase. The primary efficacy measure was change from baseline to end of treatment/last observation carried forward (EOT/LOCF) in weekly mean pain score on the DPRS. Secondary efficacy measures included pain, anxiety, sleep interference, treatment satisfaction and Patient and Clinician Global Impression of Change.
RESULTS:
Pregabalin significantly reduced the weekly mean pain score on DPRS from baseline to EOT/LOCF [-3.8 (95% CI: -4.2 to -3.3); p < 0.0001]. Reductions from baseline to EOT/LOCF were observed for all secondary efficacy outcomes (p < 0.0001). Pain and sleep interference were significantly improved compared with baseline across all weeks of the study, as early as 1 week after initiation of pregabalin (p < 0.0001). The most common adverse events (AEs) were somnolence, dizziness, weight gain and peripheral oedema. Nine (7.4%) patients discontinued the study because of AEs and 25 (20.7%) temporarily stopped or reduced their pregabalin dose because of AEs.
CONCLUSIONS:
Flexible-dose pregabalin (150-600 mg/day) significantly reduced pain and anxiety and improved sleep and was generally well tolerated in Latin American patients with neuropathic pain.
AuthorsM Xochilcal-Morales, E M Castro, J Guajardo-Rosas, T N Obregón, J C Acevedo, J M G Chucan, R Plancarte-Sanchez, G Davila, D Wajsbrot, M Guerrero, R Vinueza
JournalInternational journal of clinical practice (Int J Clin Pract) Vol. 64 Issue 9 Pg. 1301-9 (Aug 2010) ISSN: 1742-1241 [Electronic] England
PMID20487048 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Analgesics
  • Pregabalin
  • gamma-Aminobutyric Acid
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Analgesics (administration & dosage, adverse effects)
  • Colombia
  • Dose-Response Relationship, Drug
  • Ecuador
  • Female
  • Humans
  • Male
  • Mexico
  • Middle Aged
  • Neuralgia (drug therapy)
  • Pain Measurement
  • Peru
  • Pregabalin
  • Prospective Studies
  • Treatment Outcome
  • Venezuela
  • Young Adult
  • gamma-Aminobutyric Acid (administration & dosage, adverse effects, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: